Management of primary biliary cirrhosis

Jazrawi R, Caestecker J, Goggin P, et al.: Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994, 106:134–142.

Yamazaki K, Suzuki K, Nakamura A, et al.: Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999, 30:71–78.

Calmus Y, Gane P, Rouger P, et al.: Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990, 11:12–15.

Neuman M, Angulo P, Malkiewicz I, et al.: Tumor necrosis factor-alpha and transforming growth factorbeta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002, 17:196–202.

Poupon R, Chretien Y, Poupon R, et al.: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis. Lancet 1987, 1:834–836.

Poupon R, Balkau B, Eschwege E, et al.: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991, 324:1548–1554.

Heathcote E, Cauch-Dudek K, Walker V, et al.: The canadian multicenter double-blind randomized contolled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149–1156.

Lindor K, Rolland Dickson E, Baldus W, et al.: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284–1290.

Poupon R, Lindor K, Cauch-Dudek K, et al.: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884–890.

Goulis J, Leandro G, Burroughs A: Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analyis. Lancet 1999, 354:1053–1060.

Lindor K, Poupon R, Poupon R, et al.: Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000, 355:657–658.

Poupon R: Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past-issues for the future. J Hepatol 2000, 32:685–688.

Combes B, Carithers R, Maddrey W, et al.: A randomized, double-blind, placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759–766.

Erickson L, Olsson R, Glauman H, et al.: Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multi-centre, double-blind, randomized controlled study. Scand J Gastroenterol 1997, 32:179–186.

Lindor K, Jorgensen R, Therneau T, et al.: Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997, 72:1137–1140.

Angulo P, Batts K, Therneau T, et al.: Long term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29:644–647.

Corpechot C, Carrat F, Bonnand A, et al.: The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196–1199.

Pares A, Caballeria L, Rodes J, et al.: Long term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000, 32:561–566.

Angulo P, Lindor K, Therneau T, et al.: Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999, 19:115–121.

Bonnand A, Heathcote E, Lindor K, et al.: Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999, 29:39–43.

Angulo P, Rolland Dickson E, Therneau T, et al.: Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830–835.

Jones E, Bergasa N: The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 1999, 11:623–631.

Bergasa N, Talbot T, Alling D, et al.: A controlled trial of naloxone infusions for the pruritus of cholestasis. Gastroenterology 1992, 102:544–549.

Bergasa N, Alling D, Talbot T, et al.: Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind randomised controlled trial. Ann Intern Med 1995, 123:161–167.

Wolfhagen F, Sternieri E, Hop W, et al.: Oral naltrexone for cholestatic pruritus—a double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264–1269.

Bergasa N, Schmitt J, Talbot T, et al.: Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998, 27:679–684.

Schworer H, Hartmann H, Ramadori G: Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61:33–37.

Menon K, Angulo P, Weston S, et al.: Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001, 35:316–323. Well-conducted study evaluating the prevalence of osteoporosis in a large cohort of patients with PBC. It determined that those with more advanced liver disease have a faster rate of bone loss. Other predictors of increased risk of bone disease were older age and lower body mass index (<24).

Hulley S, Furberg C, Barrett-Connor E, et al.: Noncardiovascular disease outcomes during 6.8 years of hormone therapy (HERS II). JAMA 2002, 288:58–66.

Lindor K, Jorgensen R, Tiegs R, et al.: Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000, 33:878–882.

Shiraki M, Shiraki Y, Aoki C, et al.: Vitamin K2 effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000, 15:515–521.

Phillips J, Angulo P, Petterson T, et al.: Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001, 96:2745–2750.

Pasha T, Heathcote E, Gabriel S, et al.: Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999, 29:21–26.

Drug Topics Red Book. Montvale, NJ: Medical Economics; 2002.

Cauduro SC, Wiesner RH, Brandhagen DJ, et al.: Long term results of patients undergoing liver transplantation for primary biliary cirrhosis at a single center. Hepatology 2001, 34:253A.

Heathcote E, Stone J, Cauch-Dudek K, et al.: Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transplant Surg 1999, 5:269–274.